Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: CUBRC, INC.
Awarding agency: Department of Health and Human Services / Food and Drug Administration
Funding agency: Department of Health and Human Services / Food and Drug Administration
Period of performance: 2020-09-28 to 2022-09-27
Current total value of award: $1155442.55
Description: BAA CONTRACT ENTITLED "IMMUNOGENICITY RISK OF PEPTIDE DRUG GENERICS AND THEIR IMPURITIES: IN SILICO AND IN VITRO ASSESSMENT AND VALIDATION METHODS" - FUNDS DEOBLIGATION AND CONTRACT CLOSEOUT.